80.05 +0.10 (0.13%)
Pre-Market: 7:06AM EDT
|Bid||80.00 x 500|
|Ask||80.43 x 600|
|Day's Range||79.55 - 81.21|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.68|
|Dividend & Yield||2.08 (2.56%)|
|1y Target Est||N/A|
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
AbbVie's yield is higher than those of its peers, but expiring patents on the company's top-selling drug does make it a bit riskier than other dividend payers in healthcare.
Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.
Only one-third of 1% of Americans had such high prescription costs last year, but they account for more than a fifth of the spending in the category.
Juno Therapeutics stock has been on the move as investors speculate on the next CAR-T buyout target. But there are other compelling reasons to own this stock right now.
Leerink's Geoffrey Porges and Bradley Canino recently reviewed the Hepatitis C (HCV) market, and increased their price targets on Gilead (GILD) and AbbVie (ABBV) They write that both stocks are likely to enjoy a duopoly for HCV "in perpetuity," as other competitors like Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Merck (MRK) have scaled back their efforts. More from the note: After the recent announcements from JNJ (returning the rights to Achillion’s [ACHN] HCV NS5a inhibitor) and Merck (halting further development of uprifosbuvir), and the prior discontinuation of further investment into HCV at Bristol Myers after their unsuccessful investment into Inhibitex, it is now clear that the HCV category will come down to only two committed participants, Gilead and AbbVie.
Biotech is booming. After particularly rough endings to 2015 and 2016, iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has had “a rockstar of a year,” and the last two weeks, in particular, have ...
A streak of good news, the world's top-selling drug, and a strong pipeline. Is AbbVie simply the best biotech around?